Stephanie Link, TIAA Global Asset Management Portfolio Manager, went looking for value in the Healthcare sector on today's Halftime Report.
Link thinks investors should be watching Abbott Labs.
Although she says Abbott Labs has "substantially lagged" in the med-tech sector, she still believes the stock is a buy. Stephanie argues the stock trades at a rare discount to its peers and has large emerging market exposure.
One thing that has been weighing on the stock is its recent deal with St. Jude Medical, but Link thinks this deal will be good for the company in the long term.
"I think once it closes, which is in the 4th quarter of this year, you're going to see good synergy; something to the tune of like 5 to 6% sustainable total top line revenue growth and 10 to 11% bottom line growth , that's going to be better than their peers," said Link.
Link is long Abbott Labs.
Trader disclosure: Stephanie Link owns Abbott Laboratories.